View Older Stories View More Recent Stories

Aug 31, 2018 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Complete Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Aug 31, 2018 07:30AM Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Aug 30, 2018 04:00PM Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences
Aug 7, 2018 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results
Aug 1, 2018 07:40AM Arrowhead Pharmaceuticals (ARWR) Reports $10 Million Milestone Payment from Amgen
Aug 1, 2018 07:30AM Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
Jul 24, 2018 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results
Jun 29, 2018 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Highlights New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
Jun 29, 2018 07:30AM Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
Jun 27, 2018 07:33AM Arrowhead Pharmaceuticals Corp (ARWR) Granted Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
Jun 27, 2018 07:30AM Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
Jun 18, 2018 07:30AM Arrowhead Pharmaceuticals Corp (ARWR) Announces Complete Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Jun 18, 2018 07:30AM Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Jun 8, 2018 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
May 30, 2018 07:39AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Complete Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
May 30, 2018 07:30AM Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
May 30, 2018 07:25AM Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences
May 21, 2018 07:30AM Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
May 14, 2018 07:34AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Dosing of 1st Hepatitis B Patient in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
May 14, 2018 07:30AM Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
May 11, 2018 07:30AM Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline
May 8, 2018 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results
May 1, 2018 07:30AM Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics
Apr 24, 2018 04:01PM Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results
Apr 11, 2018 07:06AM Arrowhead Pharmaceuticals Corp (ARWR) Announces Clinical Data on ARC-520 at International Liver Congress 2018
Apr 11, 2018 07:00AM Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
Mar 28, 2018 07:32AM Arrowhead Pharmaceuticals Corp (ARWR) Announces Multiple Presentations at The International Liver Congress
Mar 28, 2018 07:30AM Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
Mar 27, 2018 07:34AM Arrowhead Pharmaceuticals Corp (ARWR) Commences Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
Mar 27, 2018 07:30AM Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
Mar 20, 2018 04:05PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Mar 12, 2018 07:30AM Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Mar 6, 2018 07:30AM Arrowhead to Present at Barclays Global Healthcare Conference 2018
Feb 22, 2018 07:34AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Feb 22, 2018 07:30AM Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Feb 15, 2018 01:34PM Arrowhead Pharmaceuticals Corp (ARWR) Confirms Orphan Drug Status for ARO-AAT
Feb 15, 2018 01:32PM Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
Feb 15, 2018 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Says it Was Cleared to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
Feb 15, 2018 07:30AM Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
Feb 9, 2018 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
Feb 2, 2018 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results
Dec 27, 2017 04:00PM Arrowhead Pharmaceuticals Corp (ARWR) Appoints William Waddill to Board of Directors
Dec 27, 2017 04:00PM Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors
Dec 22, 2017 07:33AM Arrowhead Pharmaceuticals Corp (ARWR) Files for Clearance to Start Phase 1/2 Study of ARO-HBV
Dec 22, 2017 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV
Dec 20, 2017 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Announces Filing of Regulatory Clearance to Begin Phase 1 Study of ARO-AAT
Dec 20, 2017 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT
Dec 18, 2017 06:27PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4)
Dec 12, 2017 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results
Dec 6, 2017 08:46AM Arrowhead (ARWR) Presents New Data Showing Sustained Host Response in HBV Patients Following RNAi Therapy
View More Recent Stories View Older Stories